Design Therapeutics 公司 DT-216P2 在1 Mpk剂量下将M-FARS评分改善6.4分,直立稳定性提升2.7分

美股速递
May 18

Design Therapeutics, Inc. 公布的数据显示,其候选药物DT-216P2在1毫克/千克(Mpk)的剂量水平下,取得了积极的疗效结果。具体而言,该治疗使患者的M-FARS(改良弗里德赖希共济失调评定量表)评分显著改善了6.4分。同时,在衡量患者平衡能力的直立稳定性指标上,也观察到了2.7分的提升。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10